| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Dr. Wolinsky) and Radiology (Dr. Narayana), The University of Texas–Houston Health Science Center; Department of Neurology (Dr. Noseworthy), The Mayo Clinic, Rochester, MN; Department of Neurology (Dr. Lublin), MCP Hahnemann University, Philadelphia, PA; Department of Neurology (Dr. Whitaker), The University of Alabama–University Hospital, Birmingham; and Pharmacia & Upjohn (Drs. Linde, Gjörstrup, and Sullivan), Kalamazoo, MI. Supported by Pharmacia & Upjohn, Kalamazoo, MI.
Address correspondence and reprint requests to Dr. Jerry S. Wolinsky, The University of Texas–Houston, Health Science Center, 6431 Fannin Street, Houston, TX 77030.
OBJECTIVE: To determine the safety and efficacy of roquinimex (linomide) in the management of relapsing-remitting and secondary progressive MS as monitored by MRI.
BACKGROUND: Preclinical studies and several short term randomized trials of linomide suggested clinical and MRI-measured benefits with acceptable risk for closely followed MS patients.
METHODS: The North American Linomide Trial formally screened 853 individuals for relapsing or secondary progressive, clinically definite MS; recent disease activity or progression; and an Expanded Disability Status Scale score at entry of 3.0 to 6.5 inclusive. MRI was obtained on 811 subjects at pre-enrollment, 718 cases at enrollment, and then at three monthly intervals until the trial was prematurely terminated for unacceptable toxicity.
RESULTS: Enhancement was found on 40.2% of 718 entry scans. Statistically robust correlations were found between clinical demographic data and several entry MRI measures including CSF volume, a reflection of brain atrophy. Assessment of the effect of treatment on MRI-measured disease was limited by early trial termination. However, active treatment for 3 months reduced the proportion of patients with one or more enhancements. An exploratory analysis suggested that 2.5 mg was the most active of three doses tested in limiting the total volume of enhanced tissue, the proportion of MRI-defined lesions designated as "black holes," and by a novel MRI composite disease measure.
CONCLUSIONS: The short term signature of the effect of linomide on MRI-measured aspects of the disease suggests that safer drugs of this class might be useful in the management of MS. The use of a composite index of the heterogeneous nature of the pathology of MS as captured by MRI may have merit as an outcome measure in clinical trials.
Key words: Linomide—MS—Treatment—MRI
This article has been cited by other articles:
|
|
 |
|
  R. Bakshi, M. Neema, B. C. Healy, Z. Liptak, R. A. Betensky, G. J. Buckle, S. A. Gauthier, J. Stankiewicz, D. Meier, S. Egorova, et al. Predicting Clinical Progression in Multiple Sclerosis With the Magnetic Resonance Disease Severity Scale Arch Neurol, November 1, 2008; 65(11): 1449 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rovaris, E. Judica, J. Sastre-Garriga, A. Rovira, M. Pia Sormani, B. Benedetti, T. Korteweg, N. De Stefano, Z. Khaleeli, X. Montalban, et al. Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis Multiple Sclerosis, May 1, 2008; 14(4): 455 - 464. [Abstract] [PDF]
|
|
|
|
|
|
A. Pulizzi, M. Rovaris, E. Judica, M. P. Sormani, V. Martinelli, G. Comi, and M. Filippi Determinants of Disability in Multiple Sclerosis at Various Disease Stages: A Multiparametric Magnetic Resonance Study Arch Neurol, August 1, 2007; 64(8): 1163 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Lisak Neurodegeneration in multiple sclerosis: Defining the problem Neurology, May 29, 2007; 68(22_suppl_3): S5 - S12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.K.B. Li, U. Held, J. Petkau, M. Daumer, F. Barkhof, F. Fazekas, J. A. Frank, L. Kappos, D. H. Miller, J. H. Simon, et al. MRI T2 lesion burden in multiple sclerosis: A plateauing relationship with clinical disability Neurology, May 9, 2006; 66(9): 1384 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H F McFarland and S C Reingold The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic eraa Multiple Sclerosis, December 1, 2005; 11(6): 669 - 676. [Abstract] [PDF]
|
|
|
|
|
|
C. Polman, F. Barkhof, M. Sandberg-Wollheim, A. Linde, O. Nordle, T. Nederman, and for the Laquinimod in Relapsing MS Study Group Treatment with laquinimod reduces development of active MRI lesions in relapsing MS Neurology, March 22, 2005; 64(6): 987 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Bielekova and R. Martin Development of biomarkers in multiple sclerosis Brain, July 1, 2004; 127(7): 1463 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S Wolinsky and PROMiSe Trial Study Group The PROMiSe trial: baseline data review and progress report Multiple Sclerosis, June 1, 2004; 10(1_suppl): S65 - S72. [Abstract] [PDF]
|
|
|
|
|
|
J. S Wolinsky and PROMiSe Trial Study Group The PRO MiSe trial: baseline data review and progress report Multiple Sclerosis, May 1, 2004; 10(3_suppl): S65 - S72. [Abstract] [PDF]
|
|
|
|
|
|
F. Bagnato, N. Jeffries, N. D. Richert, R. D. Stone, J. M. Ohayon, H. F. McFarland, and J. A. Frank Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years Brain, August 1, 2003; 126(8): 1782 - 1789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Leigh, J Ostuni, D Pham, A Goldszal, B K Lewis, T Howard, N Richert, H McFarland, and J A Frank Estimating cerebral atrophy in multiple sclerosis patients from various MR pulse sequences Multiple Sclerosis, October 1, 2002; 8(5): 420 - 429. [Abstract] [PDF]
|
|
|
|
|
|
H. McFarland, F. Barkhof, J. Antel, and D. Miller The role of MRI as a surrogate outcome measure in multiple sclerosis Multiple Sclerosis, September 1, 2002; 8(1_suppl): 40 - 51. [Abstract] [PDF]
|
|
|
|
|
|
J. Wolinsky MRI aspects of secondary progressive multiple sclerosis Multiple Sclerosis, September 1, 2002; 8(1_suppl): 85 - 87. [PDF]
|
|
|
|
|
|
D. H. Miller, F. Barkhof, J. A. Frank, G. J. M. Parker, and A. J. Thompson Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance Brain, August 1, 2002; 125(8): 1676 - 1695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Filippi and R. I. Grossman MRI techniques to monitor MS evolution: The present and the future Neurology, April 23, 2002; 58(8): 1147 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H F McFarland, F Barkhof, J Antel, and D H Miller The role of MRI as a surrogate outcome measure in multiple sclerosis Multiple Sclerosis, February 1, 2002; 8(1): 40 - 51. [Abstract] [PDF]
|
|
|
|
|
|
J S Wolinsky MRI aspects of secondary progressive multiple sclerosis Multiple Sclerosis, February 1, 2002; 8(1): 85 - 87. [PDF]
|
|
|
|
|
|
S. A. Brod, J. W. Lindsey, F. S. Vriesendorp, C. Ahn, E. Henninger, P. A. Narayana, and J. S. Wolinsky Ingested IFN-{alpha}: Results of a pilot study in relapsing-remitting MS Neurology, September 11, 2001; 57(5): 845 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. O'Connor, L. Lee, P. T. Ng, P. Narayana, and J. S. Wolinsky Determinants of overall quality of life in secondary progressive MS: A longitudinal study Neurology, September 11, 2001; 57(5): 889 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rovaris, G. Comi, M. A. Rocca, J. S. Wolinsky, and M. Filippi Short-term brain volume change in relapsing-remitting multiple sclerosis: Effect of glatiramer acetate and implications Brain, September 1, 2001; 124(9): 1803 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Filippi, J. S. Wolinsky, M.P. S. PhD, and G. Comi Enhancement frequency decreases with increasing age in relapsing-remitting multiple sclerosis Neurology, February 13, 2001; 56(3): 422 - 423. [Full Text] [PDF]
|
|
|
|
|
|
J. S Wolinsky, P. A Narayana, K. P Johnson, and Copolymer 1 Multiple Sclerosis Study Group and the United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates Multiple Sclerosis, February 1, 2001; 7(1): 33 - 41. [Abstract] [PDF]
|
|
|
|
|
|
J. T. Phillips Rethinking Multiple Sclerosis Arch Neurol, January 1, 2001; 58(1): 30 - 32. [Full Text] [PDF]
|
|
|
|
|
|
J. N. Whitaker, J. S. Wolinsky, P. A. Narayana, A. A. Bartolucci, J. H. Noseworthy, F. D. Lublin, A. Linde, P. Gjorstrup, H. C. Sullivan, and for the North American Linomide Investigators Relationship of Urinary Myelin Basic Protein-Like Material With Cranial Magnetic Resonance Imaging in Advanced Multiple Sclerosis Arch Neurol, January 1, 2001; 58(1): 49 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Schwid, A. D. Goodman, B. R. Apatoff, P. K. Coyle, L. D. Jacobs, L. B. Krupp, A. E. Miller, K. E. Wende, C. M. Brownscheidle, and a. t. New York State Multiple Sclerosis Consortium* Are quantitative functional measures more sensitive to worsening MS than traditional measures? Neurology, December 26, 2000; 55(12): 1901 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Schwid and J. L. Trotter Lessons from linomide: A failed trial, but not a failure Neurology, May 9, 2000; 54(9): 1716 - 1717. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
